Resources
-
Use of Artificial Intelligence for Process and Analytical Method Development
Roundtable Notes: Session 2 Table 12 WCBP 2026
Use of Artificial Intelligence for Process and Analytical Method Development -
Strategies for Leveraging Clinical Stability Data for Commercial Shelf Life
Roundtable Notes: Session 1 Table 15 WCBP 2026
Strategies for Leveraging Clinical Stability Data for Commercial Shelf Life -
Speed to Clinic - Phase-Appropriate Strategies to Accelerate CMC Development Timelines
Roundtable Notes: Session 1 Table 4 WCBP 2026
Speed to Clinic - Phase-Appropriate Strategies to Accelerate CMC Development Timelines -
Recent Trends in Questions from Health Authorities [Session 2]
Roundtable Notes: Session 2 Table 1 WCBP 2026
Recent Trends in Questions from Health Authorities [Session 2] -
Recent Trends in Questions from Health Authorities [Session 1]
Roundtable Notes: Session 1 Table 1 WCBP 2026
Recent Trends in Questions from Health Authorities [Session 1] -
Novel Applications of Molecular and Structural Biology in Characterization of Well Characterized Biologics
Roundtable Notes: Session 1 Table 3 WCBP 2026
Novel Applications of Molecular and Structural Biology in Characterization of Well Characterized Biologics -
Novel Applications of Molecular and Structural Biology in Characterization of ATMPS
Roundtable Notes: Session 2 Table 3 WCBP 2026
Novel Applications of Molecular and Structural Biology in Characterization of ATMPS -
In-Use Studies - Compatibility and Stability Studies
Roundtable Notes: Session 2 Table 17 WCBP 2026
In-Use Studies - Compatibility and Stability Studies -
Interpreting Confidence Intervals in Analytical Validation under ICH Q2(R2): From Statistical Reporting to Decision-Making
Roundtable Notes: Session 2 Table 11 WCBP 2026
Interpreting Confidence Intervals in Analytical Validation under ICH Q2(R2): From Statistical Reporting to Decision-Making -
ICHQ6 - Challenges and Opportunities for Using an Enhanced Approach to Lifecycle Management of Specifications [Session 2]
Roundtable Notes: Session 2 Table 7 WCBP 2026
ICHQ6 - Challenges and Opportunities for Using an Enhanced Approach to Lifecycle Management of Specifications [Session 2] -
ICHQ6 - Challenges and Opportunities for Using an Enhanced Approach to Lifecycle Management of Specifications [Session 1]
Roundtable Notes: Session 1 Table 7 WCBP 2026
ICHQ6 - Challenges and Opportunities for Using an Enhanced Approach to Lifecycle Management of Specifications [Session 1] -
How to Move From Pilot Initiatives to Sustainable Programs
Roundtable Notes: Session 2 Table 10 WCBP 2026
How to Move From Pilot Initiatives to Sustainable Programs -
Host Cell Proteins and Host Cell DNA Risk Assessment for Gene Therapies
Roundtable Notes: Session 1 Table 17 WCBP 2026
Host Cell Proteins and Host Cell DNA Risk Assessment for Gene Therapies -
Host Cell Proteins (HCP) and Host Cell DNA Risk Assessment for Gene Therapies
Roundtable Notes: Session 2 Table 15 WCBP 2026
Host Cell Proteins (HCP) and Host Cell DNA Risk Assessment for Gene Therapies -
Host Cell Protein Assays- Are We Still Relying on Conventional Quantification by Enzyme-Linked Immunosorbent Assays (ELISAs)?
Roundtable Notes: Session 1 Table 13 WCBP 2026
Host Cell Protein Assays- Are We Still Relying on Conventional Quantification by Enzyme-Linked Immunosorbent Assays (ELISAs)? -
Expectations for the Development and Application of Extended Characterization Methods [Session 2]
Roundtable Notes: Session 2 Table 5 WCBP 2026
Expectations for the Development and Application of Extended Characterization Methods -
Expectations for the Development and Application of Extended Characterization Methods [Session 1]
Roundtable Notes: Session 1 Table 5 WCBP 2026
Expectations for the Development and Application of Extended Characterization Methods -
Challenges When Working with Contract Development Manufacturing Organizations (CDMOs)
Roundtable Notes: Session 2 Table 16 WCBP 2026
Challenges When Working with Contract Development Manufacturing Organizations (CDMOs) -
Challenges and Best Practices for Global Implementation of Analytical Procedures –Use of the Analytical Target Profile as Described in ICH Q14
Roundtable Notes: Session 1 Table 14 WCBP 2026
Challenges and Best Practices for Global Implementation of Analytical Procedures –Use of the Analytical Target Profile as Described in ICH Q14 -
Best Practices in Peptide Map/MS/MS Analysis of Degradation Products and Disulfide Linkage Analysis
Roundtable Notes: Session 1 Table 10 WCBP 2026
Best Practices in Peptide Map/MS/MS Analysis of Degradation Products and Disulfide Linkage Analysis